UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 2, 2005
Commission File No. 0-11178
-------
UTAH MEDICAL PRODUCTS, INC.
---------------------------
(Exact name of Registrant as specified in its charter)
UTAH 87-0342734
------------------------------- ------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7043 South 300 West
Midvale, Utah 84047
---------------------------------------
Address of principal executive offices
Registrant's telephone number: (801) 566-1200
--------------
--------------------------------------------------------------------------------
ITEM 7.01 - REGULATION FD DISCLOSURE
--------------------------------------------------------------------------------
The U.S. Court has granted the government's (FDA's/plaintiff's) Motion for
an Extension of Time for Discovery, and modified the Scheduling Order in Case
No. 2:04CV00733 BSJ. UTMD is the defendant in this case.
All discovery is to be completed by May 2, 2005. This represents a two
month extension from the prior schedule.
The final pretrial conference is scheduled for June 20, 2005. This
represents a five week extension from the prior schedule.
Under SEC Fair Disclosure regulations, the Company feels it needs to
disseminate this information.
--------------------------------------------------------------------------------
SIGNATURES
--------------------------------------------------------------------------------
Pursuant to the requirements of the Securities Exchanges Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
---------------------------
REGISTRANT
Date: 3/02/05 By: \s\ Kevin L. Cornwell
------------------- -------------------------
Kevin L. Cornwell
Chairman & CEO